LAMP2A as a therapeutic target in Parkinson disease

Autophagy

Volumn 9, Issue 12, 2013, Pages 2166-2168

  Xilouri, Maria ^a   Brekk, Oeystein Roed ^a   Kirik, Deniz ^b   Stefanis, Leonidas ^a,c  

^a BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Alpha synuclein; Chaperone mediated autophagy; Dopaminergic system; LAMP2A; Neurotoxicity; Parkinson disease; Substantia nigra

Indexed keywords

ALPHA SYNUCLEIN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2;

ADENO ASSOCIATED VIRUS; BRAIN; BRAIN CELL CULTURE; CELL CULTURE; CELL SURVIVAL; CHAPERONE-MEDIATED AUTOPHAGY; DOPAMINERGIC NERVE CELL; HUMAN; IMMUNOREACTIVITY; MESENCEPHALON; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SHORT SURVEY; SUBSTANTIA NIGRA; UPREGULATION;

ALPHA-SYNUCLEIN; CHAPERONE-MEDIATED AUTOPHAGY; DOPAMINERGIC SYSTEM; LAMP2A; NEUROTOXICITY; PARKINSON DISEASE; SUBSTANTIA NIGRA;

ALPHA-SYNUCLEIN; ANIMALS; CELLS, CULTURED; DEPENDOVIRUS; GENETIC THERAPY; HUMANS; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 2; MOLECULAR TARGETED THERAPY; PARKINSON DISEASE; RATS; TRANSGENES;

EID: 84890829178     PISSN: 15548627     EISSN: 15548635     Source Type: Journal    
DOI: 10.4161/auto.26451     Document Type: Short Survey

References (0)